Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_1

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

NCT02200718
unknownphase_2

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

NCT02057159
unknownphase_2

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

NCT02149706

Clinical Trials (3)

Showing 3 of 3 trials
NCT02200718Phase 1

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Unknown
NCT02057159Phase 2

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Unknown
NCT02149706Phase 2

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3